Routine primary prophylaxis for febrile neutropenia with biosimilar granulocyte colony-stimulating factor (nivestim) or pegfilgrastim is cost effective in non-Hodgkin lymphoma patients undergoing curative-intent R-CHOP chemotherapy

10.1371/journal.pone.0148901

Saved in:
Bibliographic Details
Main Authors: Wang X.J., Tang T., Farid M., Quek R., Tao M., Lim S.T., Wee H.L., Chan A.
Other Authors: PHARMACY
Format: Article
Published: Public Library of Science (PLoS) 2018
Online Access:http://scholarbank.nus.edu.sg/handle/10635/142662
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: National University of Singapore
id sg-nus-scholar.10635-142662
record_format dspace
spelling sg-nus-scholar.10635-1426622024-04-05T09:00:15Z Routine primary prophylaxis for febrile neutropenia with biosimilar granulocyte colony-stimulating factor (nivestim) or pegfilgrastim is cost effective in non-Hodgkin lymphoma patients undergoing curative-intent R-CHOP chemotherapy Wang X.J. Tang T. Farid M. Quek R. Tao M. Lim S.T. Wee H.L. Chan A. PHARMACY 10.1371/journal.pone.0148901 PLoS ONE 11 2 e0148901 2018-05-30T07:08:28Z 2018-05-30T07:08:28Z 2016 Article Wang X.J., Tang T., Farid M., Quek R., Tao M., Lim S.T., Wee H.L., Chan A. (2016). Routine primary prophylaxis for febrile neutropenia with biosimilar granulocyte colony-stimulating factor (nivestim) or pegfilgrastim is cost effective in non-Hodgkin lymphoma patients undergoing curative-intent R-CHOP chemotherapy. PLoS ONE 11 (2) : e0148901. ScholarBank@NUS Repository. https://doi.org/10.1371/journal.pone.0148901 19326203 http://scholarbank.nus.edu.sg/handle/10635/142662 000370054100070 Public Library of Science (PLoS) Scopus
institution National University of Singapore
building NUS Library
continent Asia
country Singapore
Singapore
content_provider NUS Library
collection ScholarBank@NUS
description 10.1371/journal.pone.0148901
author2 PHARMACY
author_facet PHARMACY
Wang X.J.
Tang T.
Farid M.
Quek R.
Tao M.
Lim S.T.
Wee H.L.
Chan A.
format Article
author Wang X.J.
Tang T.
Farid M.
Quek R.
Tao M.
Lim S.T.
Wee H.L.
Chan A.
spellingShingle Wang X.J.
Tang T.
Farid M.
Quek R.
Tao M.
Lim S.T.
Wee H.L.
Chan A.
Routine primary prophylaxis for febrile neutropenia with biosimilar granulocyte colony-stimulating factor (nivestim) or pegfilgrastim is cost effective in non-Hodgkin lymphoma patients undergoing curative-intent R-CHOP chemotherapy
author_sort Wang X.J.
title Routine primary prophylaxis for febrile neutropenia with biosimilar granulocyte colony-stimulating factor (nivestim) or pegfilgrastim is cost effective in non-Hodgkin lymphoma patients undergoing curative-intent R-CHOP chemotherapy
title_short Routine primary prophylaxis for febrile neutropenia with biosimilar granulocyte colony-stimulating factor (nivestim) or pegfilgrastim is cost effective in non-Hodgkin lymphoma patients undergoing curative-intent R-CHOP chemotherapy
title_full Routine primary prophylaxis for febrile neutropenia with biosimilar granulocyte colony-stimulating factor (nivestim) or pegfilgrastim is cost effective in non-Hodgkin lymphoma patients undergoing curative-intent R-CHOP chemotherapy
title_fullStr Routine primary prophylaxis for febrile neutropenia with biosimilar granulocyte colony-stimulating factor (nivestim) or pegfilgrastim is cost effective in non-Hodgkin lymphoma patients undergoing curative-intent R-CHOP chemotherapy
title_full_unstemmed Routine primary prophylaxis for febrile neutropenia with biosimilar granulocyte colony-stimulating factor (nivestim) or pegfilgrastim is cost effective in non-Hodgkin lymphoma patients undergoing curative-intent R-CHOP chemotherapy
title_sort routine primary prophylaxis for febrile neutropenia with biosimilar granulocyte colony-stimulating factor (nivestim) or pegfilgrastim is cost effective in non-hodgkin lymphoma patients undergoing curative-intent r-chop chemotherapy
publisher Public Library of Science (PLoS)
publishDate 2018
url http://scholarbank.nus.edu.sg/handle/10635/142662
_version_ 1800913271705829376